医药信用评价新规将出：全面从严，失信药企须降价“整改”

Core Viewpoint - The upcoming revision of the medical pricing and procurement credit evaluation system aims to address issues of inflated drug prices and rapid growth in medical expenses caused by unethical practices such as kickbacks and monopolistic behaviors [1][2]. Group 1: Credit Evaluation System - The National Healthcare Security Administration (NHSA) will soon release a revised version of the medical pricing and procurement credit evaluation system, which includes a new list of dishonest practices and operational guidelines for credit evaluation [1]. - The credit evaluation system was initially established in September 2020 to promote fair market competition and legitimate profits by linking legal judgments and administrative penalties to corporate credit ratings [2][3]. - The previous list of dishonest practices included actions such as providing kickbacks to medical institutions, issuing false VAT invoices, and engaging in price manipulation [1]. Group 2: Current Status of Dishonest Enterprises - As of the end of 2024, there are 735 existing dishonest enterprises, including 7 classified as particularly serious, 40 as serious, 76 as medium, and 612 as general dishonest enterprises [2]. - Many dishonest enterprises have recognized their issues and taken proactive measures, such as price reductions, to restore their credit [2]. Group 3: Future Directions of the Credit Evaluation System - The revision of the credit evaluation system will adjust the classification from four tiers to three, namely "dishonest," "seriously dishonest," and "particularly seriously dishonest," while lowering the threshold for the "particularly seriously dishonest" category [3]. - The NHSA plans to enhance inter-departmental collaboration by incorporating findings from audit departments as sources of dishonest practices [3]. - The revisions aim to impose stricter penalties on pharmaceutical companies involved in bribery and collusion during centralized procurement processes, with the ultimate goal of reducing inflated drug prices [3].